<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00727129</url>
  </required_header>
  <id_info>
    <org_study_id>P04-001</org_study_id>
    <nct_id>NCT00727129</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Divigel for the Treatment of Postmenoupausal Symptoms</brief_title>
  <official_title>Placebo-Controlled, Randomized, Double-Blind, Multicenter Study, to Demonstrate the Efficacy of 12 Weeks of Treatment With USL-221 on Moderate to Severe Vasomotor Symptoms and Vulvar/Vaginal Atrophy in Postmenopausal Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Upsher-Smith Laboratories</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Upsher-Smith Laboratories</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and efficacy of USL-221 to placebo for
      postmenopausal patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">August 2005</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Daily frequency and severity of moderate to severe vasomotor symptoms</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>vulvar and vaginal atrophy</measure>
  </secondary_outcome>
  <enrollment type="Actual">495</enrollment>
  <condition>Postmenopausal Symptoms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Divigel</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal women

          -  Have moderate to severe hot flashes

          -  Normal Pap Smear

        Exclusion Criteria:

          -  Abnormal mammogram

          -  Abnormal clinical breast exam

          -  BMI &gt;35
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://www.expert-reviews.com/action/doSearch?action=runSearch&amp;type=advanced&amp;result=true&amp;prevSearch=%2Bauthorsfield%3A(Hedrick,%20Richard%20E)</url>
  </link>
  <results_reference>
    <citation>Hedrick RE. Low-dose estradiol gel 0.1% for the treatment of vasomotor symptoms associated with menopause. Expert Review of Obstetrics &amp; Gynecology, 3(2): Pages 155-162, Mar 2008.</citation>
  </results_reference>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 29, 2008</study_first_submitted>
  <study_first_submitted_qc>July 31, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2008</study_first_posted>
  <last_update_submitted>September 25, 2008</last_update_submitted>
  <last_update_submitted_qc>September 25, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2008</last_update_posted>
  <responsible_party>
    <name_title>Upsher-Smith (Medical Affairs)</name_title>
    <organization>Upsher-Smith Laboratories</organization>
  </responsible_party>
  <keyword>vasomotor symptoms</keyword>
  <keyword>estrogen</keyword>
  <keyword>estradiol</keyword>
  <keyword>hot flashes</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

